PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
First Claim
1. A method of treating a GSK-3 mediated condition, comprising administering to a patient a therapeutically effective amount of a compound of formula I
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to compounds useful as inhibitors of protein kinases, such as inhibitors of GSK-3. The invention provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention provides processes for preparing compounds of the invention. The invention provides methods of identifying compounds useful for treatment of diabetes, diabetic neuropathy, osteoporosis, Alzheimer'"'"'s disease, Huntington'"'"'s disease, Parkinson'"'"'s disease, AIDS-associated dementia, bipolar disorder, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, post-stroke, spinal cord injury, traumatic brain injury, Charcot-Marie-Tooth, peripheral nerve regeneration, and rheumatoid arthritis.
83 Citations
79 Claims
- 1. A method of treating a GSK-3 mediated condition, comprising administering to a patient a therapeutically effective amount of a compound of formula I
-
47. (canceled)
- 51. A method for treating a GSK-3 mediated condition comprising administering an agent comprising a compound selected from
-
52. (canceled)
-
55. (canceled)
-
56. (canceled)
-
57. (canceled)
-
58. (canceled)
-
59. (canceled)
-
60. (canceled)
-
61. (canceled)
-
62. (canceled)
-
63. (canceled)
-
64. (canceled)
-
65. (canceled)
-
66. A method for identifying compounds useful for the treatment of GSK-3-mediated conditions comprising:
measuring the amount of auto-phosphorylation of the tyrosine of the GSK-3 enzyme relative to the serine/threonine kinase form for one or more test compounds.
-
67. A method for identifying compounds useful for the treatment of GSK-3-mediated conditions comprising:
-
measuring the amount of auto-phosphorylation of the tyrosine of the GSK-3 enzyme and measuring the amount of phosphorylation of β
-catenin. - View Dependent Claims (68)
-
-
69. (canceled)
-
70. (canceled)
-
71. (canceled)
-
72. (canceled)
-
73. (canceled)
-
74. (canceled)
-
75. (canceled)
-
76. (canceled)
-
77. (canceled)
-
78. (canceled)
-
79. A compound selected from
Specification